Search & Analyze
Popular Searches
Rubicon Research Ltd.
BSE · 30 Oct, 4:01 PM
- ₹26,650.14 Cr
- 92.47
- 19,565
- ₹1,627.75 - ₹1,537.95
- ₹1,896.15 - ₹607.30
Rubicon Research Ltd. (RUBICON) share price closed at ₹1,609.90 on the BSE on Friday, October 30, 2026, up by 3.16% from its of ₹1,560.65. In that session RUBICON reached a of 1,627.75 and of 1,537.95. The for the session was 1,599.52. The stands at 1,665.36 and is at 1,201.64. Looking at , the stock ended the session in Uptrend.
Stock Overview
₹1,559.25
₹1,560.65
₹1,599.52
₹1,665.36
Price 3.33% below
₹1,201.64
Price 33.98% above
Peer Comparison
| Name | |||||||||
|---|---|---|---|---|---|---|---|---|---|
SUN PHARMA. SUNPHARMA | 1,778.25 | 38.91 | 4,26,661.74 | 0.90 | 1,995.07 | -36.16% | 16,198.71 | 11.88% | 19.11 |
DIVI'S LAB. DIVISLAB | 9,715.00 | 88.17 | 2,57,902.73 | 0.31 | 902.00 | 65.50% | 3,080.00 | 27.80% | 21.51 |
TORRENT PHAR TORNTPHARM | 4,635.15 | 83.01 | 1,76,306.21 | 0.82 | 534.00 | -9.64% | 4,979.00 | 50.79% | 19.27 |
LAURUSLABS LAURUSLABS | 2,392.00 | 96.46 | 1,29,242.68 | 0.08 | 436.19 | 124.27% | 2,206.37 | 33.44% | 18.20 |
ZYDUSLIFE ZYDUSLIFE | 1,244.00 | 27.50 | 1,24,089.48 | 0.08 | 990.20 | -34.90% | 8,017.00 | 21.96% | 21.39 |
DR.REDDY'S DRREDDY | 1,350.20 | 40.25 | 1,12,698.53 | 0.59 | 913.20 | -31.69% | 8,697.80 | -1.48% | 13.75 |
CIPLA LTD. CIPLA | 1,380.00 | 38.48 | 1,11,488.55 | 0.94 | 851.51 | -37.08% | 7,403.93 | -2.44% | 16.00 |
Rubicon Research Ltd. RUBICON | 1,609.90 | 92.47 | 26,650.14 | 0.09 | 84.78 | 95.79% | 534.34 | 51.59% | 29.22 |
Quarterly Results
consolidated figures in ₹ Crores · Quarterly
Profit & Loss
consolidated figures in ₹ Crores · Annual
Balance Sheet
consolidated figures in ₹ Crores
Cash Flow
consolidated figures in ₹ Crores
Ratios
Valuation
Profitability
Leverage & Liquidity
Returns
Mutual Funds Invested(88)
Based on each fund's latest monthly portfolio · Sep 2026
A total of 44 active funds hold 13.70% in Rubicon Research Ltd., contributing to ₹3.67K Cr of holdings
Corporate Actions
Insider Trading
Sector Overview
Rubicon Research Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.
Company Profile
Corporate information and contact details
Company Information
Industry
Pharmaceuticals & Drugs
Founded
1999
Headquarters
Thane, Maharashtra
Group
Private
Chairman
Venkat Changavalli
Managing Director
Pratibha Pilgaonkar
Company Secretary
Deepashree Tanksale
Face Value
₹1
CIN
L73100MH1999PLC119744
Get in Touch
Key Management
14 members across the board and senior leadership
Deepashree Tanksale
Company Secretary & Compliance Officer
—
Pratibha Pilgaonkar
Managing Director
₹1.76 Cr
Mar '26
Pratibha Sudhir Pilgaonkar
Managing Director
—
Parag Suganchand Sancheti
Whole Time Director & CEO
₹5.60 Cr
Mar '26
Venkat Changavalli
Chairman
₹25.00 L
Mar '26
Pratik Umesh Shah
Company Secretary
—
K G Ananthakrishnan
Non Executive Independent Director
₹25.00 L
Mar '26
Milind Anil Patil
Non Executive Independent Director
—
Milind Patil
Non Executive Independent Director
₹30.00 L
Mar '26
Kumarapuram Gopalakrishnan Ananthakrishnan
Non Executive Independent Director
—
Pradnya Saravade
Non Executive Independent Director
₹4.00 L
Mar '26
Changavalli Venkat
Non Executive Independent Director
—
Shantanu Rastogi
Non Independent & Non Executive Director
—
Varun Talukdar
Non Independent & Non Executive Director
—
RUBICON Latest News
News
7 of 7 articlesRubicon Research informs about updates
General Atlantic sells 8.4% stake in Rubicon Research
General Atlantic Singapore RR has sold stake through open market transactions worth around Rs 2,299.61 crore
Rubicon Research informs about disclosure
Rubicon Research soars on acquiring manufacturing facility in New Jersey, US
This site will focus on the company’s specialty and high value products as well as demand from US government departments
Rubicon Research acquires manufacturing facility in New Jersey, US
This site will focus on the company’s specialty and high value products as well as demand from US government departments
USFDA completes unannounced inspection at Rubicon Research’s Pithampur facility
Upon conclusion of the inspection, a Form 483 containing 2 observations was issued to the company
Rubicon Research reports Profit after tax of Rs 700.20 Mln, in the March 2026 quarter